X

Read Important Information on Helixate® FS, Antihemophilic Factor (Recombinant)

Read Important Information on Helixate® FS, Antihemophilic Factor (Recombinant)

For adult and pediatric patients with hemophilia A

Help Him REACH HIGHER With Long-lasting Protection

AFSTYLA, with twice-weekly dosing available, delivers long-lasting bleed protection using a novel single-chain design

Explore the benefits of AFSTYLA

Twice-weekly dosing

FDA approved for 2x–3x weekly dosing
 

View AFSTYLA
steady state data

ZERO bleeds (median AsBR*)

In all studied populations
 
 

Explore AFSTYLA efficacy

*Annualized spontaneous bleeding rate in clinical trials (IQR=0–2.4 for patients ≥12 years; 0–2.2 for patients <12 years).

BINDING AFFINITY
STABILIZES FACTOR VIII

Enhanced von Willebrand
factor affinity extends time
in circulation1

Learn about the
science of AFSTYLA

Request information

Have a CSL Behring representative contact you or sign up for updates and information about AFSTYLA

Submit a request

Call 1-800-676-4266

A My SourceSM Care Coordinator is standing by—Monday through Friday, 8 am to 8 pm ET—to provide you detailed information about services available to your patients.

Reference: 1. Zollner S, Raquet E, Claar P, et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2014;134(1):125-131.

You are now leaving the current website.

Do you want to continue?

No Yes